Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Assembly Biosciences, Inc. - Common Stock (NQ:ASMB)

23.75 +0.79 (+3.44%)
Streaming Delayed Price Updated: 10:17 AM EDT, Jun 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 18,691
Open 23.67
Bid (Size) 23.48 (200)
Ask (Size) 24.02 (100)
Prev. Close 22.96
Today's Range 23.50 - 24.15
52wk Range 16.50 - 39.70
Shares Outstanding 52,121,309
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Assembly Biosciences Teases Gilead HSV-2 Decision, Liver Disease Data Ahead ↗
Assembly Biosciences (NASDAQ:ASMB) outlined its antiviral and liver disease development strategy during a fireside chat at the 47th Annual Goldman Sachs Healthcare Conference, highlighting upcoming... 
Via MarketBeat
News headline image
Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline Expands ↗
Assembly Biosciences (NASDAQ:ASMB) is awaiting a key development plan from partner Gilead Sciences for its herpes simplex virus programs while advancing ABI-6250 into multiple liver disease... 
Via MarketBeat

Performance

YTD
-29.6%
-29.6%
1 Month
-17.1%
-17.1%
3 Month
-17.4%
-17.4%
6 Month
-31.4%
-31.4%
1 Year
+37.8%
+37.8%

More News

Read More
News headline image
Assembly Biosciences Announces Upcoming Investor Conference Presentations
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Assembly Biosciences, Inc.
Via GlobeNewswire
Assembly Biosciences Stock Jumps After Wall Street Says Gilead Opt-In ‘Significantly De-Risks’ Genital Herpes Programs ↗
Via Stocktwits
News headline image
Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Touts HSV, Hepatitis D Catalysts at BofA Conference ↗
Via MarketBeat
News headline image
Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital Herpes at ESCMID Global 2026
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Assembly Biosciences Inc (NASDAQ:ASMB) Fits the Minervini Trend Template with Strong Growth Fundamentals ↗
Via Chartmill
News headline image
Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Inc (NASDAQ:ASMB) Fits the Minervini Trend Template with High Growth Momentum ↗
Via Chartmill
News headline image
Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting®
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Forecasting The Future: 4 Analyst Projections For Assembly Biosciences ↗
Via Benzinga
News headline image
Assembly Biosciences Announces Upcoming Investor Conference Participation
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Via Benzinga
News headline image
Assembly Biosciences Announces Pricing of $175 Million in Equity Financings
From Assembly Biosciences, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Assembly Biosciences, Inc. - Common Stock publicly traded?
Yes, Assembly Biosciences, Inc. - Common Stock is publicly traded.
What exchange does Assembly Biosciences, Inc. - Common Stock trade on?
Assembly Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Assembly Biosciences, Inc. - Common Stock?
The ticker symbol for Assembly Biosciences, Inc. - Common Stock is ASMB on the Nasdaq Stock Market
What is the current price of Assembly Biosciences, Inc. - Common Stock?
The current price of Assembly Biosciences, Inc. - Common Stock is 23.75
When was Assembly Biosciences, Inc. - Common Stock last traded?
The last trade of Assembly Biosciences, Inc. - Common Stock was at 06/15/26 10:17 AM ET
What is the market capitalization of Assembly Biosciences, Inc. - Common Stock?
The market capitalization of Assembly Biosciences, Inc. - Common Stock is 1.24B
How many shares of Assembly Biosciences, Inc. - Common Stock are outstanding?
Assembly Biosciences, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.